Atorvastatin and low-density lipoprotein subfractions profile in mixed hyperlipidaemia: a contributory effect of reduced hepatic lipase activity?
Landray et al,' recently reported that the lowdensity lipoprotein (LDL) sub fraction profile can be improved by atorvastatin when given to patients with pure hypercholestrolaemia. We can confirm their findings in patients with hypertriglyceridaemia associated with hypercholesterolaemia. Ten patients (six men, four women; 44-69 years old; mean ± 1 SD total cholesterol concentration: 9·39± !'55mmol/L; LDL-C: 6·85± 1·63 mmol/L; high-density lipoprotein (HDL)-C 1·32± 0-44 mmol/L; triglycerides: 3·93 ± 1·08 mmol/L) were given atorvastatin (lOmg per day for 4
Ann cu« Biochem 1999: 36 weeks and 20 mg per day for another 4 weeks). The analysis of LDL subfractions isolated by using density gradient ultracentrifugatiorr' showed a preponderance of the dense, small LDL 3 [LDL 1 (rnean j-I SD): 16·1 ± 13%; LDL 2 : 32± 12%; LDL 3 : 52±22%] before commencement of atorvastatin therapy, as has previously been shown in primary combined hyperlipidaemia.? With atorvastatin therapy, total cholesterol, LDL cholesterol and triglyceride levels were 40%, 54% and 32% lower, respectively, than without atorvastatin therapy. The HDLcholesterol concentration was not significantly modified. The concentrations of LDL 1 and LDL 2 were not significantly changed while that of LDL 3 decreased by 68%. Landray et at. postulated that the decrease in the small LDL fraction is due to reduced formation: the reduction in triglycerides in response to atorvastatin leads to reduced formation of triglyceridesrich LDL from which the small LDL are formed by the action of hepatic lipase. We suggest that another mechanism could be involved. Indeed, we found that hepatic lipase activity" in our patients decreased from 357 ± 195 (mean ± I SD) before atorvastatin to 292± 149mU/mL with atorvastatin therapy (-18%; P<0·03). There was no significant correlation between changes in LDL 3 concentration and changes in hepatic lipase, perhaps due to the small number of patients studied.
Thus, we confirm that atorvastatin has not only a strong hypolipidaemic action but also bears the unique capacity among statins to potently reduce the atherogenic fraction of LDL. This effect is observed in patients with mixed hyperlipidaemia as much as in patients with hypercholesterolaemia. The mechanism could be partially explained by a reduction of hepatic lipase, leading to reduced formation of small dense LDL. However, like Landray et al., we think that these findings ought to be confirmed by a randomized, double-blind, placebo-controlled study. We read with interest the paper by Mathews et al., I in which the authors report that measurement of cotinine concentration, to assess nicotine intake, may be a better predictor of poor pregnancy outcome than self-reported smoking, and should be considered as a screening tool. We have taken the measurement of smoking in pregnancy one step further by the use of a 5-min near-patient urine test to measure nicotine and its metabolites by a colorimetric reaction.' The quantitative test can be operated by unskilled personnel to give an assessment of a patient's smoking habit while they are present in the clinic, thus negating the need for sample processing and transport, and removing the delay of laboratory testing. The test can be used as a screening tool to correctly identify all smokers, and patients (and midwives) can have immediate information about their smoking habit. During a randomized case--eontrol study we identified a deception rate of 9'2%, with 32-4% of smokers under-reporting their cigar-
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ette consumption to midwives. During the intervention we tested positive more than 100 women at recruitment and followed them through to 36 weeks' gestation. We also provided practical advice about smoking cessation. This led to an overall decline in nicotine intake, with an increase in the number of women who quit smoking, and a rise in the number who reduced their cigarette use. Mathews reported that cotinine concentration measurements had a better likelihood ratio and positive predictive value of adverse pregnancy outcome than did self-reporting of smoking. We found nicotine metabolite measurements correlated better with smoking-related increases to white blood cell count, mean cell volume and mean cell haemoglobin concentration than did self-reporting of cigarette consumption. Self-reporting is increasingly regarded as a poor assessment of smoking habit, and nicotine metabolite measurements, preferably undertaken at the point of care, can be used to identify those women at greatest risk of problems during pregnancy. These patients should then be offered specialist smoking cessation counselling, with follow-up during their antenatal care.
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